MISSISSAUGA, ON / ACCESSWIRE / April 20, 2023 / Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV) (OTCQX:CVALF), an advanced medical technologies company, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 at 8:30 AM PDT. Brian Pedlar, President & CEO, will be hosting the presentation and answering questions at the conclusion of the presentation.
To access the live presentation, please use the following information:
Planet MicroCap Showcase: VEGAS 2023
Date: Wednesday, April 26, 2023
Time: 11:30 AM Eastern Time (8:30 AM Pacific Time)
Webcast:https://www.webcaster4.com/Webcast/Page/2963/47976
Covalon is an innovation-driven medical device company with a strong portfolio of patented dressings and technology that make it easier for health care providers to protect patients from infection and help patients heal. Whether suffering from a chronic wound, recovering from a surgery, or undergoing treatment that requires vascular insertions, patients benefit from Covalon's family of FDA-approved products and technology that are designed to reduce complications during treatments.
Brian Pedlar recently discussed Covalon and its prospects during a Planet MicroCap interview with host Robert Kraft, which can be viewed at: https://www.youtube.com/watch?v=gzscXv7qaTI
If you would like to book 1x1 investor meetings with Covalon, and to attend the Planet MicroCap Showcase: VEGAS 2023, please make sure you are registered here: https://planetmicrocapshowcase.com/signup
1x1 meetings will be scheduled and conducted in person at the conference venue in LAS VEGAS.
The Planet MicroCap Showcase: VEGAS 2023 website is available here: https://planetmicrocapshowcase.com/
If you can't make the live presentation, all company presentations "webcasts" will be available directly on the conference event platform on this link under the tab "Agenda": https://planetmicrocapshowcase.com/agenda
News Compliments of Accesswire
About Covalon
Covalon Technologies Ltd. is a patient-driven medical device company, built on the relentless pursuit to help the most vulnerable patients have a better chance at healing. Through a strong portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, we offer innovative, gentler, and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Our solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon's name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTCQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com.
About Planet MicroCap
Planet MicroCap is a global multimedia financial news, publishing and events company focused on news dissemination, providing information, data and analytics for the MicroCap investing community. We have cultivated an active and engaged audience of folks that are interested in learning about and to stay ahead of the curve in the MicroCap space.
If you would like to attend the Planet MicroCap Showcase, please register here: https://planetmicrocapshowcase.com/signup
Contact:
Name: Brian Pedlar, CEO, Covalon Technologies Ltd.
Phone: 905.568.8400 x 233
Address: 1660 Tech Ave., Unit 5, Mississauga, ON, Canada, L4W 5S7
Email:This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | C$3.10 |
Daily Change: | -0.04 -1.27 |
Daily Volume: | 6,990 |
Market Cap: | C$84.940M |
September 11, 2024 February 28, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB